Zonegran [zonisamide] in the treatment of binge eating disorder associated with obesity: A single center, double-blind, placebo-controlled, flexible-dose study in outpatients

Trial Profile

Zonegran [zonisamide] in the treatment of binge eating disorder associated with obesity: A single center, double-blind, placebo-controlled, flexible-dose study in outpatients

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2011

At a glance

  • Drugs Zonisamide (Primary)
  • Indications Binge-Eating Disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2011 Actual initiation date (Aug 2005) added as reported by ClinicalTrials.gov.
    • 21 Jun 2011 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 12 Mar 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 12 Mar 2009
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top